Midodrine therapy for vasopressor dependent shock in the intensive care unit: a protocol for a systematic review and meta-analysis. Issue 11 (23rd November 2022)

• Record Type: Journal Article
• Authors: Kamaleldin, Mostafa; Kilcommons, Sebastian; Opgenorth, Dawn; Fiest, Kirsten; Karvellas, Constantine Jason; Kutsogiannis, Jim; Lau, Vincent; MacIntyre, Erika; Rochwerg, Bram; Senaratne, Janek; Slemko, Jocelyn; Sligl, Wendy; Wang, Xiaoming; Bagshaw, Sean M; Rewa, Oleksa G
• Is Part Of: BMJ open. Volume 12:Issue 11(2022)
• Publication Date: 2022-11-23
• Subjects: INTENSIVE & CRITICAL CARE -- Adult intensive & critical care -- ORAL MEDICINE; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2022-064060
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Intensive care unit (ICU) lengths of stay are modified by ongoing need for haemodynamic support in critically ill patients. This is most commonly provided by intravenous vasopressor therapy. Midodrine has been used as an oral agent for haemodynamic support in patients with orthostatic hypotension or cirrhosis. However, its efficacy in treating shock in the ICU, particularly for patients weaning from intravenous vasopressors, remains uncertain. The objective of this systematic review is to determine the efficacy of midodrine in vasopressor dependent shock. Methods and analysis: We will search Ovid MEDLINE, Ovid Embase, CINAHL and Cochrane Library for observational trials and randomised controlled trials evaluating midodrine in critically ill patients from inception to 21 April 2022. We will also review unpublished data and relevant conference abstracts. Outcomes will include ICU length of stay, duration of intravenous vasopressor support, ICU mortality, hospital mortality, hospital length of stay and rates of ICU readmission. Data will be analysed in aggregate, where appropriate. We will evaluate risk of bias using the modified Cochrane tool and certainty of evidence using Grading of Recommendations, Assessment, Development and Evaluations methodology. We will perform trial sequential analysis for the outcome of ICU length of stay. Ethics and dissemination: Ethics approval is not required as primary data will not be collected. Findings of this review will be disseminated through peer-related publication and will inform future clinical trials. PROSPERO registration number: CRD42021260375.